Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2020-06-15 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter from an underwriter (A.G.P./Alliance Global Partners) to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1 related to BioCardia, Inc. It references securities regulations and the distribution of a preliminary prospectus. The content is a correspondence related to the registration and offering process, not a financial report, earnings release, or other detailed filings. The document length is short (1749 characters) and it is a formal communication about the registration process, not the registration statement itself or a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory communications that do not fit other categories.
2020-06-15 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It is a formal communication related to the registration process for securities, specifically requesting the SEC to declare the Form S-1 effective by a certain date and time. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to the filing process rather than a report or announcement of financial results. The document length is short (2018 characters), and it is clearly a regulatory filing or correspondence with the SEC. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and correspondence with the SEC.
2020-06-15 English
FORM S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the SEC by BioCardia, Inc. It is a regulatory filing related to the registration of securities for a public offering, including common stock and pre-funded warrants. The document includes details about the offering, underwriting, risk factors, and other disclosures typical of a registration statement for an initial or follow-on public offering. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-06-15 English
FORM FWP
Regulatory Filings Classification · 95% confidence The document is titled 'Issuer Free Writing Prospectus' (FWP) and is filed pursuant to Rule 433 under the Securities Act of 1933. FWPs are typically used as supplemental offering materials related to a registration statement and are not full financial reports or earnings releases. The document is very short (293 characters) and does not contain financial data or detailed analysis. It is a regulatory filing related to securities offering disclosures. Therefore, the best classification is Regulatory Filings (RNS).
2020-06-08 English
FORM S-1/A
Regulatory Filings Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 1 filed with the SEC by BioCardia, Inc. It is a regulatory filing related to the registration of securities for a public offering, including common stock and pre-funded warrants. The document includes detailed information about the offering, underwriting, risk factors, and other disclosures typical of a registration statement amendment. It is not an annual report, earnings release, or any other financial report type. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains the full text of the filing, not just an announcement or certification.
2020-05-22 English
FORM 4
Director's Dealing
2020-05-20 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.